TIMI 14 evaluated the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction.
TIMI 14 evaluated the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction.